Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

AI-Driven Platforms Enhance Drug Discovery Collaborations

October 31, 2024 | AI-driven Therapeutics, Antibodies Development, Biologics Development, Biopharma Collaborations, Generative AI, biopharma dealmakers, biopharma investment, biopharma partner, clinical trials, dealmaking, drug discovery 

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design of innovative small-molecule and biologic drug candidates.

Generative AI platforms drive drug discovery dealmaking

The launch of ChatGPT in 2022 brought generative AI into the spotlight, demonstrating its powerful text-generation abilities. This groundbreaking technology is set to transform drug discovery, drawing significant investments and fostering collaborations within the biopharma sector.

Major biopharma companies are teaming up with AI-driven firms to create innovative antibodies and small molecules. Noteworthy partnerships include Almirall’s deal with Absci, valued at up to $650 million, and AstraZeneca’s $247 million collaboration with Absci.

Leading the way in AI-driven therapeutics are companies like Generate, Absci, BigHat Biosciences, BioMap, and Aqemia. These pioneers are leveraging AI to tackle challenging proteins and develop new biologics and small molecules.

The progress of AI-designed small molecules in clinical trials will be closely watched to see if AI can not only speed up drug discovery but also enhance clinical outcomes.

Read the full article on our Biopharma Dealmakers website.

To reach potential partners and investors for your drug discovery, contact us about advertising with Biopharma Dealmakers.

This content was provided by Springer Nature

Company Details

Springer Nature

Springer Nature

Email
Website

 Latest Content from  Springer Nature 

A decade-long fight against a brain-eating amoeba

Our Nature Custom Media team recently took on an ambitious project: producing a video that spanned two continents, covered a decade of medical progress, and navigated regulatory hurdles.

Branded or unbranded? The content strategy dilemma in clinical marketing

Branded or unbranded? In clinical marketing, this choice shapes how your message lands. Learn how to pick the right strategy for your goals, audience, and regulatory landscape.

5 mistakes to avoid when creating clinical content marketing

In this article, we’ll share 5 common mistakes that we’ve uncovered in our years of experience creating clinical content. Helping you avoid these mistakes is part of the service we...

AI-Driven Platforms Enhance Drug Discovery Collaborations

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design of innovative small-molecule and biologic drug candidates.

Hope in cancer therapy

The future looks hopeful as second-generation radiopharmaceuticals venture into uncharted territories.

Health awareness days in May

Are you marketing to clinical audiences around upcoming health awareness days?

Advertise to healthcare professionals with Springer Nature

Reach physicians and other HCPs with the publisher, Springer Nature

How to create content for health professionals

Catching the attention of time-strapped healthcare professionals is hard, but not impossible.

[Free Report] The What, How, and When of creating content for oncologists

Create content marketing that really engages healthcare professionals.

[Free Report] Optimizing content marketing for cardiologists

Use the Springer Nature report to create content that really engages your audience of healthcare professionals.